TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cognitive-Behavioral Treatment for Patients With Mild Alzheimer's Dementia: A Randomized Controlled Trial
Brief Summary: The purpose of this study is to determine whether a comprehensive cognitive-behavioral therapy-based, multi-component treatment programme is effective in the treatment of neuropsychiatric symptoms of patients with mild Alzheimer's dementia.


Options:
A: Arm Label: Problem Solving Therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Problem Solving Therapy | Arm Label: Problem Solving Therapy + Exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Problem Solving Therapy + Exercise | Arm Label: Enhanced Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Enhanced Usual Care | Intervention Type: BEHAVIORAL; Name: Problem Solving Therapy; Assigned to Arm(s): Problem Solving Therapy | Intervention Type: BEHAVIORAL; Name: Problem Solving Therapy + Exercise; Assigned to Arm(s): Problem Solving Therapy + Exercise | Intervention Type: OTHER; Name: Enhanced Usual Care; Assigned to Arm(s): Enhanced Usual Care
B: Arm Label: Psychological treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Psychological treatment | Arm Label: Cognitive training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive training | Arm Label: Treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Psychological treatment; Assigned to Arm(s): Psychological treatment | Intervention Type: BEHAVIORAL; Name: Cognitive training; Assigned to Arm(s): Cognitive training
C: Arm Label: Cognitive Behavioral Therapy (CBT); Type: EXPERIMENTAL; Interventions: Behavioral: Comprehensive, CBT-based, multi-component treatment | Arm Label: Treatment as usual (TAU); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment as usual | Intervention Type: BEHAVIORAL; Name: Comprehensive, CBT-based, multi-component treatment; Assigned to Arm(s): Cognitive Behavioral Therapy (CBT) | Intervention Type: BEHAVIORAL; Name: Treatment as usual; Assigned to Arm(s): Treatment as usual (TAU)
D: Arm Label: RDAD; Type: OTHER; Interventions: Behavioral: RDAD | Intervention Type: BEHAVIORAL; Name: RDAD; Assigned to Arm(s): RDAD

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate Efficacy and Safety of Treatment With CNTO 136 Administered Intravenously in Subjects With Active Lupus Nephritis
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of CNTO 136 administered intravenously in patients with active, International Society of Nephrology/Renal Pathology Society Class III and IV Lupus Nephritis (LN).


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: mycophenolate sodium | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: cyclophosphamide | Intervention Type: DRUG; Name: mycophenolate sodium; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): 2
B: Arm Label: Low dose Cyclophosphamide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cyclophosphamide, Drug: Azathioprine, Drug: Methylprednisolone | Arm Label: High Dose Cyclophosphamide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cyclophosphamide, Drug: Azathioprine, Drug: Methylprednisolone | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): High Dose Cyclophosphamide, Low dose Cyclophosphamide | Intervention Type: DRUG; Name: Azathioprine; Assigned to Arm(s): High Dose Cyclophosphamide, Low dose Cyclophosphamide | Intervention Type: DRUG; Name: Methylprednisolone; Assigned to Arm(s): High Dose Cyclophosphamide, Low dose Cyclophosphamide
C: Arm Label: Tacrolimus; Type: ACTIVE_COMPARATOR; Interventions: Drug: tacrolimus | Arm Label: mycophenolate mofetil; Type: ACTIVE_COMPARATOR; Interventions: Drug: mycophenolate mofetil | Intervention Type: DRUG; Name: tacrolimus; Assigned to Arm(s): Tacrolimus | Intervention Type: DRUG; Name: mycophenolate mofetil; Assigned to Arm(s): mycophenolate mofetil
D: Arm Label: CNTO 136; Type: EXPERIMENTAL; Interventions: Drug: CNTO 136 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: CNTO 136; Assigned to Arm(s): CNTO 136 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Steroids in Pediatric Acute Lung Injury/ARDS Trial: A Blinded, Placebo-controlled, Randomized Clinical Trial
Brief Summary: Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are devastating disorders associated with lung inflammation, low oxygen levels and respiratory failure in children. Prevalence of ALI ranges from 2.2 to 12 per 100,000 children per year. Using these estimates, up to 9,000 children each year will develop ALI/ARDS, which may cause upto 2,000 deaths per year. Currently, there are no specific therapies directed against ARDS/ALI in children. In adult patients, use of steroids early in the course of ARDS appears promising. There are no published clinical trials examining the use of steroids for the treatment of ALI/ARDS in children.

Hypothesis:

Subjects with ALI/ARDS receiving steroids early in the course of disease (within 72 hours) and longer than 7 days will have improved clinical outcomes as compared to placebo control group as defined by (a) a decreased duration of mechanical ventilation and (b) significantly increased PaO2/FiO2 ratios.


Options:
A: Arm Label: Hydrocortisone and fludrocortisone; Type: EXPERIMENTAL; Interventions: Drug: Hydrocortisone Fludrocortisone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Controlled; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Hydrocortisone Fludrocortisone; Assigned to Arm(s): Hydrocortisone and fludrocortisone
B: Intervention Type: DRUG; Name: hydrocortisone 200 mg/day; Assigned to Arm(s): N/A
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: saline | Arm Label: hydrocortisone; Type: EXPERIMENTAL; Interventions: Drug: Hydrocortisone | Intervention Type: DRUG; Name: Hydrocortisone; Assigned to Arm(s): hydrocortisone | Intervention Type: DRUG; Name: saline; Assigned to Arm(s): Placebo
D: Arm Label: Experimental Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: methylprednisolone | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal Saline (0.9%) | Intervention Type: DRUG; Name: methylprednisolone; Assigned to Arm(s): Experimental Group | Intervention Type: DRUG; Name: Normal Saline (0.9%); Assigned to Arm(s): Placebo Group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase II Trial of IL-2/IFN-α Plus Bevacizumab Versus IL-2/IFN-α in Metastatic Renal Cell Carcinoma (mRCC) - Danish Renal Cancer Group (DARENCA) Study-1
Brief Summary: The purpose of this study is to determine whether interleukin-2, interferon-alpha in combination with bevacizumab are effective in the treatment of metastatic renal cell carcinoma (mRCC).


Options:
A: Arm Label: First Sorafenib (Nexavar, BAY43-9006) 400 mg then 600 mg; Type: EXPERIMENTAL; Interventions: Drug: Sorafenib (Nexavar, BAY43-9006) | Arm Label: First Interferon then Sorafenib (Nexavar, BAY43-9006) 400 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon | Intervention Type: DRUG; Name: Sorafenib (Nexavar, BAY43-9006); Assigned to Arm(s): First Sorafenib (Nexavar, BAY43-9006) 400 mg then 600 mg | Intervention Type: DRUG; Name: Interferon; Assigned to Arm(s): First Interferon then Sorafenib (Nexavar, BAY43-9006) 400 mg
B: Arm Label: Lenvatinib 18 mg plus Everolimus 5 mg; Type: EXPERIMENTAL; Interventions: Drug: Lenvatinib, Drug: Everolimus | Arm Label: Lenvatinib 20 mg plus Pembrolizumab 200 mg; Type: EXPERIMENTAL; Interventions: Drug: Lenvatinib, Drug: Pembrolizumab | Arm Label: Sunitinib 50 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Intervention Type: DRUG; Name: Lenvatinib; Assigned to Arm(s): Lenvatinib 18 mg plus Everolimus 5 mg, Lenvatinib 20 mg plus Pembrolizumab 200 mg | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Lenvatinib 18 mg plus Everolimus 5 mg | Intervention Type: DRUG; Name: Pembrolizumab; Assigned to Arm(s): Lenvatinib 20 mg plus Pembrolizumab 200 mg | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Sunitinib 50 mg
C: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Cediranib Placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Cediranib | Intervention Type: DRUG; Name: Cediranib; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Cediranib Placebo; Assigned to Arm(s): 1
D: Arm Label: Interleukin-2, interferon, bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab | Arm Label: Interleukin-2 and interferon-alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interleukin-2, Drug: Interferon Alfa-2b | Intervention Type: DRUG; Name: Interleukin-2; Assigned to Arm(s): Interleukin-2 and interferon-alfa | Intervention Type: DRUG; Name: Interferon Alfa-2b; Assigned to Arm(s): Interleukin-2 and interferon-alfa | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Interleukin-2, interferon, bevacizumab

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: China-JD Program: A Multi-centre Demonstration Project to Evaluate the Effectiveness and Acceptability of the Joint Asia Diabetes Evaluation (JADE) and DIAbetes MONitoring Database (DIAMOND) Programs in Asian Type 2 Diabetic Patients
Brief Summary: Quality diabetes care requires a team approach and informed decisions of patients and care providers. Several lines of evidence suggests that a protocol-driven care model delivered by trained staff with focus on periodic assessments, reinforcement of patient compliance and attainment of multiple treatment targets reduces risk of cardio-renal complications and early death in type 2 diabetes.

The investigators hypothesize that the use of state of the art information technology to record, manage and analyze the large amount of clinical information generated during various consultation visits will improve the effectiveness and efficiency in implementing these care protocols through decision support and regular feedback to both patients and care team.


Options:
A: Arm Label: EBMeDS group; Type: EXPERIMENTAL; Interventions: Behavioral: The EBMeDS system, Other: Evidence Linker | Arm Label: Control group; Type: OTHER; Interventions: Other: Evidence Linker | Intervention Type: BEHAVIORAL; Name: The EBMeDS system; Assigned to Arm(s): EBMeDS group | Intervention Type: OTHER; Name: Evidence Linker; Assigned to Arm(s): Control group, EBMeDS group
B: Intervention Type: BEHAVIORAL; Name: Internet co-management module; Assigned to Arm(s): N/A
C: Arm Label: JADE; Type: EXPERIMENTAL; Interventions: Other: JADE | Arm Label: DIAMOND; Type: ACTIVE_COMPARATOR; Interventions: Other: DIAMOND | Intervention Type: OTHER; Name: JADE; Assigned to Arm(s): JADE | Intervention Type: OTHER; Name: DIAMOND; Assigned to Arm(s): DIAMOND
D: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Continued care; Type: EXPERIMENTAL; Interventions: Other: team-based care | Intervention Type: OTHER; Name: team-based care; Assigned to Arm(s): Continued care

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Hypothermic Machine Preservation of Extended Criteria Liver Allografts for Transplantation
Brief Summary: This is a study comparing a technique of continuous circulation to the liver as a means of preventing liver damage during transportation to the transplant hospital. This new technique of Machine Perfusion (MP) will be compared to the standard technique where the liver is maintained in a bag of solution on ice without circulation. The investigators will evaluate and compare the outcomes of the transplants with the new technique to the standard technique. There will be 24 MP patient's in the study. The investigators have previously used this technique with success in 20 human liver transplant patients. The investigators think there will be a benefit in terms of less damage to and better function of the donor liver which will result in faster recovery for the patients. This protective effect may allow us to successfully transplant more patients and prevent people from dying while waiting for a liver transplant.


Options:
A: Arm Label: Experimental: Hypothermic Machine Perfusion Group; Type: EXPERIMENTAL; Interventions: Device: The Medtronic Portable Bypass System (PBS®) | Arm Label: Matched control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: The Medtronic Portable Bypass System (PBS®); Assigned to Arm(s): Experimental: Hypothermic Machine Perfusion Group
B: Arm Label: Hypothermic oxygenated perfusion (HOPE); Type: EXPERIMENTAL; Interventions: Device: Hypothermic oxygenated perfusion (HOPE) | Arm Label: Conventional cold storage (CCS); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Conventional cold storage (CCS) | Intervention Type: DEVICE; Name: Hypothermic oxygenated perfusion (HOPE); Assigned to Arm(s): Hypothermic oxygenated perfusion (HOPE) | Intervention Type: PROCEDURE; Name: Conventional cold storage (CCS); Assigned to Arm(s): Conventional cold storage (CCS)
C: Arm Label: Dual hypothermic oxygenated perfusion; Type: EXPERIMENTAL; Interventions: Procedure: Dual hypothermic oxygenated perfusion, Device: Liver Assist®, Procedure: Perfusion fluid, Drug: Glutathione | Arm Label: Care as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Dual hypothermic oxygenated perfusion; Assigned to Arm(s): Dual hypothermic oxygenated perfusion | Intervention Type: DEVICE; Name: Liver Assist®; Assigned to Arm(s): Dual hypothermic oxygenated perfusion | Intervention Type: PROCEDURE; Name: Perfusion fluid; Assigned to Arm(s): Dual hypothermic oxygenated perfusion | Intervention Type: DRUG; Name: Glutathione; Assigned to Arm(s): Dual hypothermic oxygenated perfusion
D: Arm Label: OCS Liver System; Type: EXPERIMENTAL; Interventions: Device: OCS™ Liver System | Arm Label: Control; Type: OTHER; Interventions: Other: Control | Intervention Type: DEVICE; Name: OCS™ Liver System; Assigned to Arm(s): OCS Liver System | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Postpartum Prophylaxis for PE Randomized Control Trial Pilot: A Pilot Study Assessing Feasibility of a Randomized, Open-label Trial of Low-Molecular-Weight-Heparin for Postpartum Prophylaxis in Women at Risk of Developing Venous Thromboembolism
Brief Summary: The purpose of this study is to determine if it is feasible to conduct a multi-center randomized trial to determine whether a blood thinner, low-molecular-weight-heparin (LMWH), is effective at preventing blood clots, thromboembolism (VTE), in postpartum women at risk.


Options:
A: Arm Label: low molecular weight heparin; Type: EXPERIMENTAL; Interventions: Drug: Dalteparin Sodium | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Dalteparin Sodium; Assigned to Arm(s): low molecular weight heparin
B: Arm Label: Enoxaparin group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin | Arm Label: Warfarin group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Enoxaparin group | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin group
C: Arm Label: Enoxaparin Once Daily; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin | Arm Label: Enoxaparin Twice Daily; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Enoxaparin Once Daily, Enoxaparin Twice Daily
D: Intervention Type: DRUG; Name: Low dose steroids; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Visual Reconstitution Therapy After Optic Neuritis
Brief Summary: Incomplete remission after an optic neuritis attack is not uncommon. Visual reconstitution therapy is a software-based approach that has been shown to substantially improve residual visual field deficits in patients with pre- and postchiasmatic lesions.

The primary hypothesis of this randomized, controlled clinical trial is, that visual reconstitution therapy is superior to active comparator treatment in improving the visual field after optic neuritis.


Options:
A: Intervention Type: PROCEDURE; Name: Eccentric Viewing Training for Reading; Assigned to Arm(s): N/A
B: Arm Label: regular O&M-training; Type: ACTIVE_COMPARATOR; Interventions: Other: orientation and mobility training | Arm Label: standardised O&M-training; Type: EXPERIMENTAL; Interventions: Other: orientation and mobility training | Intervention Type: OTHER; Name: orientation and mobility training; Assigned to Arm(s): regular O&M-training, standardised O&M-training
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Other: Low Vision Intervention - Outpatient Training Program | Arm Label: Arm 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Low Vision Intervention - Outpatient Training Program; Assigned to Arm(s): Arm 1
D: Arm Label: Visual Reconstitution Therapy; Type: EXPERIMENTAL; Interventions: Other: Visual Reconstitutions Therapy | Arm Label: Saccadic Eye Movement Training; Type: ACTIVE_COMPARATOR; Interventions: Other: Saccadic Eye Movement Training | Intervention Type: OTHER; Name: Visual Reconstitutions Therapy; Assigned to Arm(s): Visual Reconstitution Therapy | Intervention Type: OTHER; Name: Saccadic Eye Movement Training; Assigned to Arm(s): Saccadic Eye Movement Training

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Perioperative Administration of Erythromycin and Brain Protection
Brief Summary: Neurological complications occur in open heart surgery with a frequency of 40% and they range from major neurological deficits (due to a stroke) to neurocognitive and behavioral disorders. This study aims to determine if erythromycin, a worldwide known antibiotic, protects the brain from damage when given in high doses before and during open heart surgery.

The investigators consume that high dose of erythromycin will protect the brain with a pharmacological preconditioning against the global ischemia during the perioperative period of heart surgery.


Options:
A: Arm Label: erythromycin group; Type: N/A; Interventions: N/A | Arm Label: control group; Type: N/A; Interventions: N/A
B: Arm Label: Doxycycline; Type: EXPERIMENTAL; Interventions: Drug: Doxycycline | Arm Label: Standard Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Current medical therapy for AMI | Intervention Type: DRUG; Name: Doxycycline; Assigned to Arm(s): Doxycycline | Intervention Type: DRUG; Name: Current medical therapy for AMI; Assigned to Arm(s): Standard Therapy
C: Arm Label: Clarithromycin; Type: EXPERIMENTAL; Interventions: Drug: clarithromycin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: clarithromycin | Intervention Type: DRUG; Name: clarithromycin; Assigned to Arm(s): Clarithromycin, Placebo
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sirolimus | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sirolimus | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sirolimus; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Sirolimus; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: cSBIRT to Reduce Teen Tobacco, Alcohol and Drug Use
Brief Summary: In this project we will conduct a pilot study of a brief intervention to reduce teen tobacco, alcohol and drug use that primary care dental practitioners can provide in their offices.


Options:
A: Arm Label: Sugar Pill; Type: PLACEBO_COMPARATOR; Interventions: Other: Sugar Pill | Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Bupropion HCl; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion HCl | Intervention Type: OTHER; Name: Sugar Pill; Assigned to Arm(s): Sugar Pill | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Bupropion HCl; Assigned to Arm(s): Bupropion HCl
B: Arm Label: Treatment as Usual Group 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Treatment as Usual Group 2; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention Group 1; Type: EXPERIMENTAL; Interventions: Behavioral: Computer Screening, Brief Intervention, Referral toTreatment | Arm Label: Intervention Group 2; Type: EXPERIMENTAL; Interventions: Behavioral: Computer Screening, Brief Intervention, Referral toTreatment | Intervention Type: BEHAVIORAL; Name: Computer Screening, Brief Intervention, Referral toTreatment; Assigned to Arm(s): Intervention Group 1, Intervention Group 2
C: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Transdermal Nicotine Patch; Type: EXPERIMENTAL; Interventions: Drug: Transdermal Nicotine Patch | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Transdermal Nicotine Patch; Assigned to Arm(s): Transdermal Nicotine Patch
D: Arm Label: Varenicline treatment as usual (TAU); Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Varenicline directly observed therapy; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline directly observed therapy, Varenicline treatment as usual (TAU)

Answer: B